期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 115, 期 41, 页码 E9600-E9609出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1807112115
关键词
BRCA1-IRIS; metastasis; HIF-1 alpha; PTEN
资金
- National Cancer Institute (NCI) Cancer Center Support Grant NIH [5P30CA06516]
- NCI [2P01CA080111]
- DFCI/Novartis Program in Drug Discovery
- Breast Cancer Research Foundation
- Susan G. Komen Foundation for the Cure
- BRCA Foundation
- NATIONAL CANCER INSTITUTE [R35CA210057, R35CA210068, P50CA101942, P30CA006516, P01CA080111] Funding Source: NIH RePORTER
BRCA1 is an established breast and ovarian tumor suppressor gene that encodes multiple protein products whose individual contributions to human cancer suppression are poorly understood. BRCA1-IRIS (also known as IRIS), an alternatively spliced BRCA1 product and a chromatin-bound replication and transcription regulator, is overexpressed in various primary human cancers, including breast cancer, lung cancer, acute myeloid leukemia, and certain other carcinomas. Its naturally occurring overexpression can promote the metastasis of patient-derived xenograft (PDX) cells and other human cancer cells in mouse models. The IRIS-driven metastatic mechanism results from IRIS-dependent suppression of phosphatase and tensin homolog (PTEN) transcription, which in turn perturbs the PI3K/AKT/GSK-3 beta pathway leading to prolyl hydroxylase-independent HIF-1 alpha stabilization and activation in a normoxic environment. Thus, despite the tumor-suppressing genetic origin of IRIS, its properties more closely resemble those of an oncoprotein that, when spontaneously overexpressed, can, paradoxically, drive human tumor progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据